LA JOLLA—The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is no cure to fully eliminate the virus from the body, so patients still often struggle with related health issues, side effects, social stigma, and drug resistance.
One of the most promising treatment avenues is disrupting HIV replication by impairing the function of integrase, a protein named for its role in integrating viral genetic material into the human host genome. However, scientists have recently noticed that integrase does more than just integration. Later in HIV’s replication cycle, integrase interacts with viral RNA to help the virus spread and infect new cells.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
